

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method of normalizing the sleep/wake cycle of a mammal, said method comprising orally administering a therapeutically-effective amount of a compound comprising cytidine, cytidine monophosphate (CMP), cytidine diphosphate (CDP), cytidine triphosphate (CTP), deoxycytidine monophosphate (dCMP), deoxycytidine diphosphate (dCDP), deoxycytidine triphosphate (dCTP), CDP-choline, cytosine, uridine, uridine monophosphate (UMP), uridine diphosphate (UDP), uridine triphosphate (UTP), or triacetyl uridine ~~thereby normalizing the sleep/wake cycle of said mammal.~~

2. (Currently amended) The method of claim 1, wherein said administration reduces fatigue or tiredness, increases wakefulness, or improves the sleep quality of said mammal ~~during the day.~~

3. (Previously presented) The method of claim 1, wherein said compound is cytidine.

4. (Cancelled)

5. (Previously presented) The method of claim 1, wherein said compound is CDP-choline.

6. (Cancelled)

7. (Previously presented) The method of claim 1, wherein said compound is CDP.

8. (Previously presented) The method of claim 1, wherein said administration is chronic.

9. (Original) The method of claim 1, wherein said mammal is a human.
10. (Original) The method of claim 9, wherein said human is a child or adolescent.
11. (Original) The method of claim 9, wherein said human is an older adult.
12. (Currently amended) A method of treating a sleep disorder, said method comprising administering to a mammal a therapeutically-effective amount of a compound comprising cytidine, cytidine monophosphate (CMP), cytidine diphosphate (CDP), cytidine triphosphate (CTP), deoxycytidine monophosphate (dCMP), deoxycytidine diphosphate (dCDP), deoxycytidine triphosphate (dCTP), CDP-choline, cytosine, uridine, uridine monophosphate (UMP), uridine diphosphate (UDP), uridine triphosphate (UTP), or triacetyl uridine, wherein said mammal's health is not compromised because of an existing physical condition.
13. (Original) The method of claim 12, wherein said sleep disorder is caused by a substance abuse disorder.
14. (Previously presented) The method of claim 13, wherein said substance abuse disorder is alcohol, caffeine, or cocaine dependence.
15. (Previously presented) The method of claim 12, wherein said sleep disorder is constructive or obstructive sleep apnea, restless leg syndrome, periodic limb movements, or narcolepsy.
16. (Previously presented) The method of claim 12, wherein said compound is CDP-choline.

17. (Currently amended) A method of increasing cognitive function in a sleep-deprived mammal, said method comprising administering a therapeutically-effective amount of a compound comprising cytidine, cytidine monophosphate (CMP), cytidine diphosphate (CDP), cytidine triphosphate (CTP), deoxycytidine monophosphate (dCMP), deoxycytidine diphosphate (dCDP), deoxycytidine triphosphate (dCTP), CDP-choline, cytosine, uridine, uridine monophosphate (UMP), uridine diphosphate (UDP), uridine triphosphate (UTP), triacetyl uridine, creatine, adenosine, adenosine monophosphate (AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP), S-adenosylmethionine, propentofylline, or EHNA to a mammal suffering from sleep deprivation, ~~thereby increasing the cognitive functioning of said mammal.~~

18. (Currently amended) The method of claim 17, wherein said ~~cytidine-~~
~~containing~~ compound is CDP-choline.

19. (Previously presented) The method of claim 12, wherein said sleep disorder is not caused by a substance abuse disorder.

20. (Previously presented) The method of claim 12, wherein said sleep disorder is problem sleepiness.

21. (Previously presented) The method of claim 12, wherein said sleep disorder is insomnia.

22. (Currently amended) A method of treating a sleep disorder, said method comprising administering to a mammal a therapeutically-effective amount of a compound

comprising cytidine, cytidine monophosphate (CMP), cytidine diphosphate (CDP), cytidine triphosphate (CTP), deoxycytidine monophosphate (dCMP), deoxycytidine diphosphate (dCDP), deoxycytidine triphosphate (dCTP), CDP-choline, cytosine, uridine, uridine monophosphate (UMP), uridine diphosphate (UDP), uridine triphosphate (UTP), triacetyl uridine, creatine, adenosine, adenosine monophosphate (AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP), S-adenosylmethionine, dipyridamole, propentofylline, or EHNA, wherein said sleep disorder is not insomnia or sleep apnea.

23. (Previously presented) The method of claim 22, wherein said sleep disorder is caused by a substance abuse disorder.

24. (Previously presented) The method of claim 23, wherein said substance abuse disorder is alcohol, caffeine, or cocaine dependence.

25. (Previously presented) The method of claim 22, wherein said sleep disorder is restless leg syndrome, periodic limb movements, or narcolepsy.

26. (Previously presented) The method of claim 22, wherein said compound is CDP-choline.

27. (Currently amended) A method of normalizing the sleep/wake cycle of a mammal, said method comprising chronically administering a therapeutically-effective amount of a compound comprising ~~cytidine~~, cytidine monophosphate (CMP), cytidine diphosphate (CDP), cytidine triphosphate (CTP), deoxycytidine monophosphate (dCMP), deoxycytidine diphosphate (dCDP), deoxycytidine triphosphate (dCTP), CDP-choline, cytosine, ~~uridine~~, uridine monophosphate (UMP), uridine diphosphate (UDP), uridine triphosphate (UTP), triacetyl uridine, creatine, ~~adenosine~~, adenosine monophosphate (AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP) S-

adenosylmethionine, dipyridamole, propentofylline, or EHNA to a mammal, ~~thereby normalizing the sleep/wake cycle of said mammal.~~

28. (Currently amended) The method of claim 27, wherein said administration reduces fatigue or tiredness, increases wakefulness, or improves the sleep quality of said mammal ~~during the day.~~

29. (Previously presented) The method of claim 27, wherein said compound is CDP-choline.

30. (Previously presented) The method of claim 1, wherein said compounds is administered in conjunction with an antidepressant, anticonvulsant, antianxiety, antimanic, antipsychotic, antiobsessional, sedative-hypnotic, or anti-hypertensive medication.